SpyGlass Pharma, Inc. Common Stock (SGP) Stock Score, Valuation & Financial Research

SpyGlass Pharma, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SGP

SpyGlass Pharma, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 24.78. These figures are a research snapshot, not a buy or sell recommendation.

What SpyGlass Pharma, Inc. Common Stock does

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

SpyGlass Pharma is a late-stage biopharmaceutical company that does not yet generate commercial revenue. It operates by developing a proprietary drug delivery platform designed to integrate approved medicines into sustained-release systems for the treatment of chronic eye conditions, currently funding its operations through capital raises and investment proceeds.

Products and services

  • The company is developing the SpyGlass Platform, which includes the BIM-IOL System (an IOL-mounted drug delivery system) and a non-IOL-based drug release system (DRS) for the treatment of glaucoma and other eye conditions.

Brands and product families

  • SpyGlass Platform — The company's core proprietary drug delivery technology platform. Source

Customer types

Ophthalmologists and eye surgeons.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its clinical trial materials and drug delivery systems; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Alcon — Manufacturer of commercially available monofocal IOLs used as comparators in clinical trials. Source
  • Bausch + Lomb — Manufacturer of commercially available monofocal IOLs used as comparators in clinical trials. Source
  • Johnson & Johnson — Manufacturer of commercially available monofocal IOLs used as comparators in clinical trials. Source

Business strengths to evaluate

  • Proprietary sustained-release drug delivery platform technology Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Risks associated with clinical trial success and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SGP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 24.78
Market capitalization:
828.48M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -56.05M
Free cash flow:
USD -33.49M
Cash:
USD 223.14M
Total debt:
USD 1.63M
EPS:
USD -1.66

What stands out

  • Free cash flow is USD -33.49M, negative for the stored period.
  • The balance sheet shows USD 223.14M of cash versus USD 1.63M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 221.51M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SGP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SGP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SGP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SGP to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of SGP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research SGP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.